**Proteins** 

# **Product** Data Sheet

## **Bleomycin A5**

Cat. No.: HY-N10470 CAS No.: 11116-32-8


Molecular Formula:  $\mathsf{C}_{57}\mathsf{H}_{89}\mathsf{N}_{19}\mathsf{O}_{21}\mathsf{S}_{2}$ 

Molecular Weight: 1440.56 Target: **Apoptosis** Pathway: **Apoptosis** 

Storage: 4°C, sealed storage, away from moisture and light

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture

and light)



### **SOLVENT & SOLUBILITY**

In Vitro

 $H_2O : \ge 100 \text{ mg/mL } (69.42 \text{ mM})$ 

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	0.6942 mL	3.4709 mL	6.9417 mL
	5 mM	0.1388 mL	0.6942 mL	1.3883 mL
	10 mM	0.0694 mL	0.3471 mL	0.6942 mL

Please refer to the solubility information to select the appropriate solvent.

### **BIOLOGICAL ACTIVITY**

Description	Bleomycin A5 (Pingyangmycin) is an orally active glycopeptide antibiotics. Bleomycin A5 has a role as an antineoplastic agent, an apoptosis inducer and a bacterial metabolite <sup>[1][2]</sup> .
In Vitro	Bleomycin A5 (Pingyangmycin) can inhibit the growth of tumor <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Bleomycin A5 (Pingyangmycin) (oral; 18 daily doses of 5 mg/kg) occurs anorexia, cachexia, skin ulcerations, and death and observes interstitial pneumonia, nephrosis and focal necrosis of the adrenal cortex <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

[1]. Yaowu Yang, et al. Bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations. J Vasc Surg. 2011 Jan;53(1):150-5.



Page 2 of 2 www.MedChemExpress.com